Abstract
Objective: Evaluate an inpatient intervention to reduce rates of hospital related complications in patients with Parkinson’s disease (PD).
Background: Several interventions have been suggested to reduce known inpatient complications in hospitalized PD patients but there are no data driven recommendations currently reported.
Design/Methods: A hospital wide alert system was incorporated into the EMR of Dignity Health affiliated hospitals in Arizona. Extensive in-services were done with providers and staff. Charts of subjects with PD admitted 6 months before and after the intervention were reviewed for baseline demographics, compliance with the intervention, and outcomes.
Results: 73 patients (mean age 73 years, mean disease duration 7.2 ± 9.1 years) in the pre-intervention group, 103 patients (mean age 72 years, mean disease duration 7.0 ± 6.4 years) in the post-intervention group were included. There were no significant differences among reasons for admission, admission to neurological vs non-neurological floor, or the service the patients were admitted to between the groups. The percentage of patients for whom contra-indicated medications ordered decreased from 42.5% to 17.5% (p<0.001). Medication administration within 30 minutes of scheduled time went from 36% to 53%, and doses given over 30 minutes went from 46% to 39% (p=0.068). Medications ordered by home schedule was 42.9% vs 54.7% (p=0.131) before and after the intervention. Length of stay was 5.3 vs 5.2 days (p=0.896) and mean number of complications was 0.38 vs 0.37 (p=0.864).
Conclusions: An intervention involving EMR alerts and in-service didactics decreased the frequency of contraindicated medications ordered in hospitalized PD patients.
Disclosure: Dr. Aslam has nothing to disclose. Dr. Simpson has nothing to disclose. Dr. Baugh has nothing to disclose. Dr. Shill has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie and Sunovion. Dr. Shill has received research support from Biogen, Dong-A ST Co., Ltd., MagQu. Intec Pharma, Ltd, US World Meds, and Sunovion/Cynapsus Therapeutics, Inc..
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg